These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 9501066)
1. Design of allele-specific inhibitors to probe protein kinase signaling. Bishop AC; Shah K; Liu Y; Witucki L; Kung C; Shokat KM Curr Biol; 1998 Feb; 8(5):257-66. PubMed ID: 9501066 [TBL] [Abstract][Full Text] [Related]
2. Engineering Src family protein kinases with unnatural nucleotide specificity. Liu Y; Shah K; Yang F; Witucki L; Shokat KM Chem Biol; 1998 Feb; 5(2):91-101. PubMed ID: 9495830 [TBL] [Abstract][Full Text] [Related]
3. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities. Liu Y; Witucki LA; Shah K; Bishop AC; Shokat KM Biochemistry; 2000 Nov; 39(47):14400-8. PubMed ID: 11087392 [TBL] [Abstract][Full Text] [Related]
4. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Liu Y; Shah K; Yang F; Witucki L; Shokat KM Bioorg Med Chem; 1998 Aug; 6(8):1219-26. PubMed ID: 9784863 [TBL] [Abstract][Full Text] [Related]
5. Structural basis for selective inhibition of Src family kinases by PP1. Liu Y; Bishop A; Witucki L; Kraybill B; Shimizu E; Tsien J; Ubersax J; Blethrow J; Morgan DO; Shokat KM Chem Biol; 1999 Sep; 6(9):671-8. PubMed ID: 10467133 [TBL] [Abstract][Full Text] [Related]
6. Engineering a "methionine clamp" into Src family kinases enhances specificity toward unnatural ATP analogues. Ulrich SM; Kenski DM; Shokat KM Biochemistry; 2003 Jul; 42(26):7915-21. PubMed ID: 12834343 [TBL] [Abstract][Full Text] [Related]
7. Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Fan QW; Zhang C; Shokat KM; Weiss WA Curr Biol; 2002 Aug; 12(16):1386-94. PubMed ID: 12194819 [TBL] [Abstract][Full Text] [Related]
8. Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth. Chang LC; Huang CH; Cheng CH; Chen BH; Chen HC J Biomed Sci; 2005; 12(4):571-85. PubMed ID: 16132110 [TBL] [Abstract][Full Text] [Related]
9. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Shah K; Liu Y; Deirmengian C; Shokat KM Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3565-70. PubMed ID: 9108016 [TBL] [Abstract][Full Text] [Related]
10. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies. He H; Hirokawa Y; Levitzki A; Maruta H Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144 [TBL] [Abstract][Full Text] [Related]
11. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148 [TBL] [Abstract][Full Text] [Related]
13. Inhibitor scaffolds as new allele specific kinase substrates. Kraybill BC; Elkin LL; Blethrow JD; Morgan DO; Shokat KM J Am Chem Soc; 2002 Oct; 124(41):12118-28. PubMed ID: 12371851 [TBL] [Abstract][Full Text] [Related]
14. Differential requirements of the MAP kinase and PI3 kinase signaling pathways in Src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells. Nguyen KT; Wang WJ; Chan JL; Wang LH Oncogene; 2000 Nov; 19(47):5385-97. PubMed ID: 11103940 [TBL] [Abstract][Full Text] [Related]
15. A chemical genetic screen for direct v-Src substrates reveals ordered assembly of a retrograde signaling pathway. Shah K; Shokat KM Chem Biol; 2002 Jan; 9(1):35-47. PubMed ID: 11841937 [TBL] [Abstract][Full Text] [Related]
16. UCS15A, a non-kinase inhibitor of Src signal transduction. Sharma SV; Oneyama C; Yamashita Y; Nakano H; Sugawara K; Hamada M; Kosaka N; Tamaoki T Oncogene; 2001 Apr; 20(17):2068-79. PubMed ID: 11360191 [TBL] [Abstract][Full Text] [Related]
17. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906 [TBL] [Abstract][Full Text] [Related]
18. Regulation of Ly49D/DAP12 signal transduction by Src-family kinases and CD45. Mason LH; Willette-Brown J; Taylor LS; McVicar DW J Immunol; 2006 Jun; 176(11):6615-23. PubMed ID: 16709819 [TBL] [Abstract][Full Text] [Related]
19. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells. Kamps MP; Sefton BM Oncogene Res; 1988 Sep; 3(2):105-15. PubMed ID: 2465525 [TBL] [Abstract][Full Text] [Related]
20. The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells. Twamley-Stein GM; Pepperkok R; Ansorge W; Courtneidge SA Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7696-700. PubMed ID: 8356071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]